vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
VIRTUS INVESTMENT PARTNERS, INC. is the larger business by last-quarter revenue ($208.0M vs $196.0M, roughly 1.1× Axsome Therapeutics, Inc.). VIRTUS INVESTMENT PARTNERS, INC. runs the higher net margin — 16.3% vs -14.6%, a 30.8% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -10.9%). Axsome Therapeutics, Inc. produced more free cash flow last quarter ($-18.7M vs $-74.1M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -3.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
AXSM vs VRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $208.0M |
| Net Profit | $-28.6M | $33.9M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 19.1% |
| Net Margin | -14.6% | 16.3% |
| Revenue YoY | 65.0% | -10.9% |
| Net Profit YoY | 61.9% | -14.2% |
| EPS (diluted) | $-0.55 | $5.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $208.0M | ||
| Q3 25 | $171.0M | $216.4M | ||
| Q2 25 | $150.0M | $210.5M | ||
| Q1 25 | $121.5M | $217.9M | ||
| Q4 24 | $118.8M | $233.5M | ||
| Q3 24 | $104.8M | $227.0M | ||
| Q2 24 | $87.2M | $224.4M | ||
| Q1 24 | $75.0M | $222.0M |
| Q4 25 | $-28.6M | $33.9M | ||
| Q3 25 | $-47.2M | $31.3M | ||
| Q2 25 | $-48.0M | $42.7M | ||
| Q1 25 | $-59.4M | $28.1M | ||
| Q4 24 | $-74.9M | $39.5M | ||
| Q3 24 | $-64.6M | $49.1M | ||
| Q2 24 | $-79.3M | $26.0M | ||
| Q1 24 | $-68.4M | $37.9M |
| Q4 25 | -13.8% | 19.1% | ||
| Q3 25 | -27.0% | 21.7% | ||
| Q2 25 | -24.5% | 21.5% | ||
| Q1 25 | -46.9% | 16.8% | ||
| Q4 24 | -61.1% | 21.7% | ||
| Q3 24 | -59.8% | 24.3% | ||
| Q2 24 | -89.5% | 19.7% | ||
| Q1 24 | -89.7% | 14.5% |
| Q4 25 | -14.6% | 16.3% | ||
| Q3 25 | -27.6% | 14.5% | ||
| Q2 25 | -32.0% | 20.3% | ||
| Q1 25 | -48.9% | 12.9% | ||
| Q4 24 | -63.1% | 16.9% | ||
| Q3 24 | -61.7% | 21.6% | ||
| Q2 24 | -91.0% | 11.6% | ||
| Q1 24 | -91.1% | 17.1% |
| Q4 25 | $-0.55 | $5.15 | ||
| Q3 25 | $-0.94 | $4.65 | ||
| Q2 25 | $-0.97 | $6.12 | ||
| Q1 25 | $-1.22 | $4.05 | ||
| Q4 24 | $-1.54 | $4.65 | ||
| Q3 24 | $-1.34 | $5.71 | ||
| Q2 24 | $-1.67 | $2.43 | ||
| Q1 24 | $-1.44 | $4.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | $390.0M |
| Stockholders' EquityBook value | $88.3M | $934.0M |
| Total Assets | $689.8M | $4.3B |
| Debt / EquityLower = less leverage | — | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — | ||
| Q1 24 | $331.4M | — |
| Q4 25 | — | $390.0M | ||
| Q3 25 | — | $390.6M | ||
| Q2 25 | — | $231.3M | ||
| Q1 25 | — | $231.7M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | — | $237.5M | ||
| Q2 24 | — | $247.6M | ||
| Q1 24 | — | $253.0M |
| Q4 25 | $88.3M | $934.0M | ||
| Q3 25 | $73.7M | $918.7M | ||
| Q2 25 | $73.1M | $896.4M | ||
| Q1 25 | $53.2M | $893.7M | ||
| Q4 24 | $57.0M | $897.5M | ||
| Q3 24 | $92.9M | $889.0M | ||
| Q2 24 | $102.9M | $868.7M | ||
| Q1 24 | $144.0M | $871.7M |
| Q4 25 | $689.8M | $4.3B | ||
| Q3 25 | $669.3M | $3.9B | ||
| Q2 25 | $639.8M | $3.7B | ||
| Q1 25 | $596.7M | $3.7B | ||
| Q4 24 | $568.5M | $4.0B | ||
| Q3 24 | $561.5M | $3.6B | ||
| Q2 24 | $548.2M | $3.6B | ||
| Q1 24 | $545.7M | $3.5B |
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.43× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.26× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $-67.2M |
| Free Cash FlowOCF − Capex | $-18.7M | $-74.1M |
| FCF MarginFCF / Revenue | -9.6% | -35.6% |
| Capex IntensityCapex / Revenue | 0.0% | 3.3% |
| Cash ConversionOCF / Net Profit | — | -1.99× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $100.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $-67.2M | ||
| Q3 25 | $1.0M | $108.3M | ||
| Q2 25 | $-32.4M | $75.8M | ||
| Q1 25 | $-43.4M | $-3.8M | ||
| Q4 24 | $-26.2M | $1.8M | ||
| Q3 24 | $-18.6M | $69.1M | ||
| Q2 24 | $-30.1M | $70.0M | ||
| Q1 24 | $-53.5M | $-34.5M |
| Q4 25 | $-18.7M | $-74.1M | ||
| Q3 25 | $988.0K | $106.9M | ||
| Q2 25 | $-32.4M | $74.2M | ||
| Q1 25 | $-43.7M | $-6.8M | ||
| Q4 24 | $-26.2M | $-3.8M | ||
| Q3 24 | $-18.7M | $68.7M | ||
| Q2 24 | $-30.2M | $68.6M | ||
| Q1 24 | $-53.6M | $-36.5M |
| Q4 25 | -9.6% | -35.6% | ||
| Q3 25 | 0.6% | 49.4% | ||
| Q2 25 | -21.6% | 35.2% | ||
| Q1 25 | -36.0% | -3.1% | ||
| Q4 24 | -22.1% | -1.6% | ||
| Q3 24 | -17.9% | 30.3% | ||
| Q2 24 | -34.6% | 30.6% | ||
| Q1 24 | -71.4% | -16.4% |
| Q4 25 | 0.0% | 3.3% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.3% | 1.4% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.1% | 0.2% | ||
| Q2 24 | 0.1% | 0.6% | ||
| Q1 24 | 0.1% | 0.9% |
| Q4 25 | — | -1.99× | ||
| Q3 25 | — | 3.45× | ||
| Q2 25 | — | 1.77× | ||
| Q1 25 | — | -0.13× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 2.69× | ||
| Q1 24 | — | -0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
VRTS
| Open End Funds | $68.9M | 33% |
| Retail Separate Accounts | $51.3M | 25% |
| Institutional Accounts | $39.6M | 19% |
| Administration And Shareholder Service Fees | $18.4M | 9% |
| Closed End Funds | $15.9M | 8% |
| Distribution And Service Fees | $12.3M | 6% |
